Shares of Keryx Biopharmaceuticals (KERX), a drug developer with a focus on renal disease, had an awful month: Shares were down nearly 40% in September.
What caused the huge downward move? See the presentation below for details.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Keryx Biopharmaceuticals Was Obliterated in September
By Brian Feroldi
–
Oct 25, 2015 at 6:01PM
NASDAQ: KERX
Keryx Biopharmaceuticals
Shares fell a huge 39% in September. Was there any news to justify the sell-off?
About the Author
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Keryx Biopharmaceuticals
KERX
iShares Trust - iShares Biotechnology ETF
IBB
$151.01
(0.93%)
$1.39
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Akebia Therapeutics Is Soaring Today
Here's Why Keryx Biopharmaceuticals Dropped 19.6% in August
Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today
Keryx Biopharma Down 17% Despite Drug Approval
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.